Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking...
Baudax Bio reported revenue of $1.27 million for fiscal year 2022, up 17.5% from fiscal year 2021, and net income of -$58.80 million.
Figures from company filings; latest fiscal year ended December 31, 2022.
No profile data available.